|
Volumn 3, Issue 4, 2001, Pages 201-205
|
Cationic antimicrobial peptides: Towards clinical applications
|
Author keywords
Antimicrobial peptides; Biotechnology; Innate immunity; Nosocomial infections
|
Indexed keywords
CATION;
CECROPIN;
DETERGENT;
POLYPEPTIDE ANTIBIOTIC AGENT;
AMINO ACID;
ANTIBIOTIC AGENT;
ANTIINFECTIVE AGENT;
DISULFIDE;
HELIOMYCIN;
ISEGANAN;
MAGAININ DERIVATIVE;
MBI 226;
MYCOPREX;
OFLOXACIN;
PEPTIDE DERIVATIVE;
PEPTIDE MBI;
PEXIGANAN;
PLACEBO;
RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN;
UNCLASSIFIED DRUG;
ADAPTATION;
ALPHA HELIX;
AMINO ACID SEQUENCE;
ANTIMICROBIAL ACTIVITY;
ARTICLE;
BACTERIUM;
BIOTECHNOLOGY;
CELL MEMBRANE;
CHANNEL GATING;
CONTROLLED STUDY;
DISULFIDE BOND;
DRUG CLASSIFICATION;
DRUG INDUSTRY;
DRUG MECHANISM;
FUNGUS;
HOST RESISTANCE;
IMMUNE RESPONSE;
MICROORGANISM;
NONHUMAN;
PROTEIN STABILITY;
CLINICAL PRACTICE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG DESIGN;
HUMAN;
MOLECULAR STABILITY;
PATHOGENICITY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
|
EID: 0035212051
PISSN: 12945501
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (4)
|
References (33)
|